Clinicians looking to take part in the process of discovery and development of new drugs and devices will have many opportunities during ATS 2013 to connect with industry exhibitors to learn more about the latest clinical trial recruitment and research.
The Clinical Trial Awareness area, which bridges the Exhibit Hall and the Registration area in the Pennsylvania Convention Center, will feature ALung Technologies and P3 Research Ltd. Attendees also will be able to find clinical trial information at the InterMune and Regeneron Pharmaceuticals, Inc., booths in the Exhibit Hall A-B (200 Level).
ALung Technologies, Inc., a provider of advanced respiratory support solutions, is seeking interested physicians for its U.S. Food and Drug Administration Investigational Device Exemption pivotal trial to participate as study site principal investigators or as independent Data Safety Monitoring Board members. Learn more about its transformative ECCO2R technology and clinical trials program in Booth 1 in the Clinical Trial Awareness area.
P3 Research Ltd., a dedicated clinical trials company with two sites in New Zealand, has 10 years of experience in undertaking early phase clinical trials in COPD and asthma. New Zealand has a high prevalence of these conditions and a favorable regulatory system, according to company. These factors coupled with a temperate climate and an experienced team of investigators make for easy, rapid start-up times and reliable conduct of such studies, according to the company, which adds that location in the southern hemisphere means recruitment through northern hemisphere winters can also be maximized. Learn more about its clinical trial recruitment in Booth 8 in the Clinical Trial Awareness area.
Regeneron Pharmaceuticals, Inc., and Sanofi are now in the process of identifying clinical trial sites for the phase 2 studies of an investigational compound under evaluation for asthma. Regeneron is a science-based biopharmaceutical company based in Tarrytown, New York, that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Sanofi discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Learn more about Regeneron and Sanofi and their clinical trials opportunities in Booth 1252 in the Exhibit Hall.
InterMune, a biotechnology company focused on the research, development, and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases is currently conducting a clinical trial in Idiopathic Pulmonary Fibrosis (IPF), ASCEND. ASCEND is a multinational, randomized, double-blind, placebo controlled Phase 3 trial designed to evaluate the safety and efficacy of Esbriet® (pirfenidone) in IPF patients with mild to moderate impairment in lung function. “Having completed in January 2013 the full enrollment of the ASCEND Phase 3 study of pirfenidone, which is intended to support U.S. marketing approval, we are much closer to the goal of bringing Esbriet to IPF patients in the United States, who currently have no approved treatment options,” said InterMune Chairman, Chief Executive Officer and President Dan Welch. InterMune will provide information about IPF and ASCEND at Booth 1245 in the Exhibit Hall.